Frontage continues build-out to meet late-stage developers demand

By Vassia Barba

- Last updated on GMT

(Image: Getty/belchonock)
(Image: Getty/belchonock)

Related tags Frontage Laboratories Bioanalytical Bioanalysis cell and gene therapy

Frontage has announced completion of its Pennsylvania site expansion to boost its offering of bioanalytical services for late-stage cell and gene therapies developers.

The addition of 10,000 square feet in its Exton, PA, laboratory space was announced​ by Frontage Laboratories in October 2019. At that point, the company stated that the expansion will enable enhancement of its capabilities in biologic drugs development.

Frontage has cut the ribbon​ at the facility, which now totals 80,000 square feet. This brings the bioanalytical capabilities additions completed during the past four months to 52,000 square feet, in an aim to support the booming R&D business of biologics.

This conclusion comes after the establishment​ of a 42,000 square foot laboratory in Shanghai, China, dedicated to bioanalytical services. Apart from its bioanalytical business, Frontage also has recently invested in scaling up its facility in New Jersey​, dedicated to nicotine-related studies.

Following the build-out completion, the facility in Exton is equipped with increased sample management and laboratory space, as well as enhanced instrumentation, systems, robotics automation, software and personnel capacity.

Frontage also has established a center of excellence supporting cell and gene therapies development at the location. The center includes dedicated laboratories in DNA/RNA sample preparation, polymerase chain reaction services, flow cytometry, and cell culture.

According to the company, the site now houses ‘greater’ biomarker, PK, and immunogenicity bioanalytical capacity, to support large clinical studies at Phase II-IV.

Related news

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Related suppliers